Among patients with resectable stage IIIA or IIIB NSCLC (non–small-cell lung cancer), those treated with neoadjuvant nivolumab plus chemotherapy have achieved a higher level of complete response and… read more.
Despite advances in surgery and chemotherapy, survival of people with certain types of ovarian cancer has not significantly changed in decades. That has meant that some ovarian cancer… read more.
Adjunctive therapy with atorvastatin appears to reduce the proportion of patients with lymphoma who are being treated with anthracyclines and who also develop cardiac dysfunction. The findings were… read more.
A study of more than 50,000 women found that continued breast cancer screening after age 70 was associated with a greater incidence of cancer that likely would not… read more.
An interim safety analysis of the first randomised controlled trial of its kind involving over 80,000 Swedish women published in The Lancet Oncology journal, finds artificial intelligence (AI)-supported mammography analysis… read more.
A new study published in Gastroenterology aims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett’s esophagus (BE). BE is the only identifiable precursor… read more.
Taiho Pharmaceutical and its subsidiary Taiho Oncology Europe have received conditional marketing authorisation from the European Commission for Lytgobi (futibatinib) tablets to treat adults with cholangiocarcinoma (CCA). The… read more.
The combination of curettage and cryosurgery is a safe and effective treatment method for the most common form of skin cancer, basal cell carcinoma. A study from the… read more.
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer… read more.
In patients with refractory metastatic colorectal cancer, fruquintinib treatment has resulted in a significant improvement in overall survival compared with placebo. Researchers reported this finding on June 15,… read more.
For patients who are progression-free after two years of frontline immunotherapy for advanced non–small cell lung cancer (NSCLC), there does not appear to be a survival benefit in… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term data from the pivotal Phase 1/II MajesTEC-1 study showing the sustained efficacy and safety of Tecvayli (teclistamab-cqyv) in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
